Esophageal pathology in patients after treatment for head and neck cancer

D Gregory Farwell, Catherine J. Rees, Debbie A. Mouadeb, Jacqueline Allen, Allen M. Chen, Danny J. Enepekides, Peter C Belafsky

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective: To determine the prevalence of esophageal pathology following treatment for primary head and neck cancer (HNCA). Study Design: Case series with planned data collection. Setting: Academic medical practice. Subjects and Methods: Subjects comprised HNCA survivors. Esophagoscopy was prospectively performed on 100 patients at least three months after treatment for HNCA. Patient demographics including cancer stage, cancer treatment, use of reflux medications, symptoms surveys, and esophageal findings were prospectively determined. Results: The mean age of the cohort was 64 (± 10) years; 75 percent were male. The mean time between the end of treatment and endoscopy was 40 (± 51) months. Eighty-one percent of HNCA was advanced stage (3 or 4). The distribution of site of the primary HNCA was as follows: oropharynx (38%), larynx (33%), oral cavity (17%), unknown primary (10%), hypopharynx (1%), and nasopharynx (1%). Treatment modalities included surgery alone (15%), surgery with radiation (34%), radiation alone (6%), chemoradiation alone (24%), and chemoradiation with surgery (20%). The findings on esophagoscopy included peptic esophagitis (63%), stricture (23%), candidiasis (9%), Barrett metaplasia (8%), gastritis (4%), and carcinoma (4%). Only 13 percent had a normal esophagoscopy. Conclusion: Esophageal pathology is extremely common in patients treated for HNCA. These findings support routine esophageal screening after HNCA treatment.

Original languageEnglish (US)
Pages (from-to)375-378
Number of pages4
JournalOtolaryngology - Head and Neck Surgery
Volume143
Issue number3
DOIs
StatePublished - Sep 2010

Fingerprint

Head and Neck Neoplasms
Pathology
Esophagoscopy
Therapeutics
Radiation
Hypopharynx
Peptic Esophagitis
Oropharynx
Barrett Esophagus
Nasopharynx
Candidiasis
Gastritis
Larynx
Endoscopy
Survivors
Mouth
Neoplasms
Pathologic Constriction
Demography
Carcinoma

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Surgery
  • Medicine(all)

Cite this

Esophageal pathology in patients after treatment for head and neck cancer. / Farwell, D Gregory; Rees, Catherine J.; Mouadeb, Debbie A.; Allen, Jacqueline; Chen, Allen M.; Enepekides, Danny J.; Belafsky, Peter C.

In: Otolaryngology - Head and Neck Surgery, Vol. 143, No. 3, 09.2010, p. 375-378.

Research output: Contribution to journalArticle

Farwell, D Gregory ; Rees, Catherine J. ; Mouadeb, Debbie A. ; Allen, Jacqueline ; Chen, Allen M. ; Enepekides, Danny J. ; Belafsky, Peter C. / Esophageal pathology in patients after treatment for head and neck cancer. In: Otolaryngology - Head and Neck Surgery. 2010 ; Vol. 143, No. 3. pp. 375-378.
@article{57751a5c10f94a55ae53a37ec3c7a87d,
title = "Esophageal pathology in patients after treatment for head and neck cancer",
abstract = "Objective: To determine the prevalence of esophageal pathology following treatment for primary head and neck cancer (HNCA). Study Design: Case series with planned data collection. Setting: Academic medical practice. Subjects and Methods: Subjects comprised HNCA survivors. Esophagoscopy was prospectively performed on 100 patients at least three months after treatment for HNCA. Patient demographics including cancer stage, cancer treatment, use of reflux medications, symptoms surveys, and esophageal findings were prospectively determined. Results: The mean age of the cohort was 64 (± 10) years; 75 percent were male. The mean time between the end of treatment and endoscopy was 40 (± 51) months. Eighty-one percent of HNCA was advanced stage (3 or 4). The distribution of site of the primary HNCA was as follows: oropharynx (38{\%}), larynx (33{\%}), oral cavity (17{\%}), unknown primary (10{\%}), hypopharynx (1{\%}), and nasopharynx (1{\%}). Treatment modalities included surgery alone (15{\%}), surgery with radiation (34{\%}), radiation alone (6{\%}), chemoradiation alone (24{\%}), and chemoradiation with surgery (20{\%}). The findings on esophagoscopy included peptic esophagitis (63{\%}), stricture (23{\%}), candidiasis (9{\%}), Barrett metaplasia (8{\%}), gastritis (4{\%}), and carcinoma (4{\%}). Only 13 percent had a normal esophagoscopy. Conclusion: Esophageal pathology is extremely common in patients treated for HNCA. These findings support routine esophageal screening after HNCA treatment.",
author = "Farwell, {D Gregory} and Rees, {Catherine J.} and Mouadeb, {Debbie A.} and Jacqueline Allen and Chen, {Allen M.} and Enepekides, {Danny J.} and Belafsky, {Peter C}",
year = "2010",
month = "9",
doi = "10.1016/j.otohns.2010.05.006",
language = "English (US)",
volume = "143",
pages = "375--378",
journal = "Otolaryngology - Head and Neck Surgery (United States)",
issn = "0194-5998",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Esophageal pathology in patients after treatment for head and neck cancer

AU - Farwell, D Gregory

AU - Rees, Catherine J.

AU - Mouadeb, Debbie A.

AU - Allen, Jacqueline

AU - Chen, Allen M.

AU - Enepekides, Danny J.

AU - Belafsky, Peter C

PY - 2010/9

Y1 - 2010/9

N2 - Objective: To determine the prevalence of esophageal pathology following treatment for primary head and neck cancer (HNCA). Study Design: Case series with planned data collection. Setting: Academic medical practice. Subjects and Methods: Subjects comprised HNCA survivors. Esophagoscopy was prospectively performed on 100 patients at least three months after treatment for HNCA. Patient demographics including cancer stage, cancer treatment, use of reflux medications, symptoms surveys, and esophageal findings were prospectively determined. Results: The mean age of the cohort was 64 (± 10) years; 75 percent were male. The mean time between the end of treatment and endoscopy was 40 (± 51) months. Eighty-one percent of HNCA was advanced stage (3 or 4). The distribution of site of the primary HNCA was as follows: oropharynx (38%), larynx (33%), oral cavity (17%), unknown primary (10%), hypopharynx (1%), and nasopharynx (1%). Treatment modalities included surgery alone (15%), surgery with radiation (34%), radiation alone (6%), chemoradiation alone (24%), and chemoradiation with surgery (20%). The findings on esophagoscopy included peptic esophagitis (63%), stricture (23%), candidiasis (9%), Barrett metaplasia (8%), gastritis (4%), and carcinoma (4%). Only 13 percent had a normal esophagoscopy. Conclusion: Esophageal pathology is extremely common in patients treated for HNCA. These findings support routine esophageal screening after HNCA treatment.

AB - Objective: To determine the prevalence of esophageal pathology following treatment for primary head and neck cancer (HNCA). Study Design: Case series with planned data collection. Setting: Academic medical practice. Subjects and Methods: Subjects comprised HNCA survivors. Esophagoscopy was prospectively performed on 100 patients at least three months after treatment for HNCA. Patient demographics including cancer stage, cancer treatment, use of reflux medications, symptoms surveys, and esophageal findings were prospectively determined. Results: The mean age of the cohort was 64 (± 10) years; 75 percent were male. The mean time between the end of treatment and endoscopy was 40 (± 51) months. Eighty-one percent of HNCA was advanced stage (3 or 4). The distribution of site of the primary HNCA was as follows: oropharynx (38%), larynx (33%), oral cavity (17%), unknown primary (10%), hypopharynx (1%), and nasopharynx (1%). Treatment modalities included surgery alone (15%), surgery with radiation (34%), radiation alone (6%), chemoradiation alone (24%), and chemoradiation with surgery (20%). The findings on esophagoscopy included peptic esophagitis (63%), stricture (23%), candidiasis (9%), Barrett metaplasia (8%), gastritis (4%), and carcinoma (4%). Only 13 percent had a normal esophagoscopy. Conclusion: Esophageal pathology is extremely common in patients treated for HNCA. These findings support routine esophageal screening after HNCA treatment.

UR - http://www.scopus.com/inward/record.url?scp=77955973587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955973587&partnerID=8YFLogxK

U2 - 10.1016/j.otohns.2010.05.006

DO - 10.1016/j.otohns.2010.05.006

M3 - Article

C2 - 20723774

AN - SCOPUS:77955973587

VL - 143

SP - 375

EP - 378

JO - Otolaryngology - Head and Neck Surgery (United States)

JF - Otolaryngology - Head and Neck Surgery (United States)

SN - 0194-5998

IS - 3

ER -